Securities Code: 301281 Securities Abbreviation: Keyuan Pharmaceutical Announcement No.: 2026-056
Shandong Keyuan Pharmaceutical Co., Ltd.
Announcement on Abnormal Stock Trading Fluctuations
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are not aware of any false representations, misleading statements, or material omissions.
Special Notes:
-
On July 2, 2026, Shandong Keyuan Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") had a Price-to-Earnings Ratio (TTM) of 267.03, which is relatively high. The cumulative increase in the closing price of the Company's stock over three consecutive trading days (June 30, 2026, July 1, 2026, and July 2, 2026) exceeded 30%, with a significant deviation from the ChiNext Index during the same period. Investors are advised to fully understand the risks of secondary market trading, make prudent decisions, and invest rationally.
-
The Company plans to disclose its 2026 interim report on August 27, 2026. The specific financial data will be subject to the relevant report disclosed by the Company. As of the date of this announcement, the preparation work for the Company's 2026 interim report is underway and no interim financial data for 2026 has been provided to any third party.
-
The Company solemnly reminds all investors: The designated information disclosure media for the Company are Securities Times, Shanghai Securities News, China Securities Journal, Securities Daily, and Juchao Information Network (http://www.cninfo.com.cn). All information concerning the Company is subject to the announcements published in the aforementioned designated media. Investors are urged to invest rationally and pay attention to investment risks.